Besides atherosclerosis, sepsis, and NASH, DPP-4 inhibitors and GLP-1 analogs exert immunomodulatory effects in various models of chronic inflammatory diseases such as colitis [249], asthma [250], chronic obstructive lung disease (COPD) [251], and rheumatoid arthritis [252]. The gene discussed is DPP4; the disease is atherosclerosis.